Our results showed that control and DOCK4-depleted cancer cells almost double their filopodia in response to EGF treatment (Fig. 3d, g), whereas upon TGFβ stimulation, the number of filopodia remained unchanged in both control and DOCK4-depleted cells (Fig. 3h). The gene discussed is TGFB1; the disease is cancer.